Every 8-K that Cencora, Inc. (COR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow COR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COR filings page.
Cencora, Inc. reported that director Lorence H. Kim, M.D., resigned from its Board of Directors effective immediately on August 13, 2026, following the conclusion of the Board’s quarterly meeting.
The company states that Dr. Kim’s decision is connected to his appointment as Chief Financial Officer of Commonwealth Fusion Systems, Inc. and his need to devote additional time to those professional responsibilities. Dr. Kim advised that his resignation is not due to any disagreement regarding Cencora’s operations, policies, or practices. The company expressed appreciation for his dedicated service.
Cencora, Inc. reports that beginning July 1, 2026, certain Walgreens volume that had been serviced separately from the existing prime vendor agreement began moving outside Cencora. The company states that the prime vendor agreement, which it describes as constituting the vast majority of its Walgreens business, remains unchanged.
Cencora also reaffirms its previously issued fiscal 2026 adjusted diluted EPS guidance in the range of $17.75 to $17.95. The company includes cautionary language that these are forward-looking statements based on current expectations and subject to risks and uncertainties described in its periodic reports.
Cencora, Inc. amended and restated its multi-currency senior unsecured revolving credit facility, increasing aggregate lender commitments to $7.0 billion from $5.5 billion and extending the maturity to July 2031. Borrowings accrue interest at margins ranging from 69.5 to 110 basis points over benchmark rates and 0 to 10 basis points over alternate base and Canadian prime rates, with covenants including a maximum financial leverage ratio and customary events of default.
The company also executed an Omnibus Amendment to its receivables securitization structure, reducing the Receivables Securitization Facility commitment from $1.5 billion to $1.0 billion while increasing the accordion feature to $1.0 billion and adding a new uncommitted purchaser. Accounts receivable originated by ABDC and ASD are sold to ARFC, which in turn sells interests to purchaser groups, with Cencora acting as performance guarantor, providing an additional liquidity and funding source for ongoing business needs.
Cencora reported strong fiscal third-quarter 2026 results, with revenue of $84.8 billion, up 5.1% year-over-year, and gross profit of $3.6 billion, up 24.1%. GAAP diluted EPS rose to $3.94 from $3.52, while adjusted diluted EPS increased to $4.48 from $4.00.
Operating income grew 29.1% to $1.1 billion, driven by higher margins in U.S. Healthcare Solutions after the February 2026 OneOncology acquisition and growth in specialty and GLP-1 products, partly offset by higher operating expenses and a 72.0% rise in net interest expense to $140.7 million. Net income attributable to Cencora was $763.5 million. For the first nine months, revenue increased 4.8% and diluted EPS reached $15.21 versus $9.70, reflecting a $1.1 billion gain on remeasurement of the prior OneOncology stake.
Outlook and capital allocation were updated: fiscal 2026 adjusted EPS guidance was raised to $17.75–$17.95; adjusted operating income is projected to grow 13–14%, revenue 4–6%, and adjusted free cash flow about $3.0 billion with approximately $900 million in capital expenditures. Cencora repurchased $1 billion of shares in the quarter and declared a $0.60 per-share dividend payable August 31, 2026.
Cencora, Inc. announced a planned leadership transition in its human resources organization. Executive Vice President and Chief Human Resources Officer Silvana Battaglia will retire from her role effective July 12, 2026, after a seven-year tenure, and continue as an advisor through the end of 2026. The company stated her decision was not due to any disagreement regarding operations, policies, or practices.
Samantha (Sam) Hammock will join Cencora as Executive Vice President and Chief Human Resources Officer effective July 13, 2026, reporting to CEO Bob Mauch and serving on the enterprise leadership team. She previously held senior HR roles at Verizon Communications and American Express. The press release highlights Cencora’s scale, including more than 51,000 team members, over $300 billion in annual revenue, and Fortune 500 and Global 500 rankings, underscoring the strategic importance of the CHRO role.
Cencora, Inc. announced that Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer, effective June 29, 2026, succeeding retiring CFO James F. Cleary, who will remain in an advisory role through the end of 2026. Boratto joins with extensive experience as former CFO of Bath & Body Works and CVS Health, and with prior senior finance roles at Merck.
Her employment package includes a $1,000,000 annual base salary, an annual bonus target equal to 100% of salary, a $2,000,000 cash sign-on bonus subject to repayment conditions, and a one-time restricted stock unit award valued at $6,000,000 with three-year ratable vesting. Cencora also reaffirmed its fiscal 2026 adjusted diluted EPS guidance range of $17.70 to $17.90, and its long-term targets of 7%–10% adjusted operating income growth and 10%–14% adjusted diluted EPS growth.
Cencora reported solid fiscal 2026 second-quarter results with revenue of $78.4 billion, up 3.8% year-over-year. GAAP diluted EPS jumped to $8.40 from $3.68, boosted by a $1.1 billion gain tied to the OneOncology acquisition, while adjusted diluted EPS rose 7.5% to $4.75.
The company raised its fiscal 2026 adjusted EPS guidance to $17.65–$17.90 from $17.45–$17.75 and now expects about $3.0 billion in adjusted free cash flow. Management also plans to repurchase $1 billion of shares by the end of calendar 2026 and declared a quarterly dividend of $0.60 per share.
Cencora, Inc. has signed a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion, expanding its Retina Consultants of America network. The affiliated retina physicians are expected to join RCA, strengthening Cencora’s position in specialized eye care.
Cencora expects the deal to be slightly accretive to adjusted diluted EPS in the first 12 months after closing, net of financing costs. The transaction is subject to customary closing conditions and required regulatory approvals. Cencora reaffirmed its fiscal 2026 financial guidance, which currently does not assume the transaction will close within that fiscal year.
Cencora, Inc. has announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer, effective June 30, 2026. He will assist with the search for a successor and continue in an advisory capacity through the end of 2026 to support a smooth leadership transition.
Cleary, age 62, has served as Cencora’s CFO since November 2018 and previously led MWI Veterinary Supply as CEO for over a decade before joining Cencora in 2015. The company stated that his retirement is not related to any disagreement over operations, policies, or practices.
Alongside the leadership news, Cencora reaffirmed its previously issued adjusted diluted EPS guidance for fiscal year 2026, maintaining a range of $17.45 to $17.75. Cencora highlights its scale as a global pharmaceutical solutions organization with more than $300 billion in annual revenue and over 51,000 team members worldwide.
Cencora, Inc. reported the results of its 2026 Annual Meeting of Shareholders held on March 5, 2026. Shareholders elected eleven directors, with support for each nominee generally ranging from about 163 million to 168 million votes in favor, with relatively few votes against or abstentions.
Shareholders also approved, on an advisory basis, the fiscal 2025 compensation of the company’s named executive officers, with 156,852,214 votes for, 11,422,390 against, and 427,407 abstentions. In addition, they ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal 2026, with 165,700,999 votes for, 12,622,687 against, and 116,893 abstentions.
Cencora has agreed to merge its animal health business, MWI Animal Health, with Covetrus, valuing MWI at an enterprise value of $3.5 billion. At closing, Cencora will receive $1.25 billion in cash plus equity in the combined parent, including $800 million of perpetual preferred units and $1.45 billion of common units.
After the merger closes and regulatory and other customary conditions are met, Cencora expects to own about 34.3% of the combined CVET TopCo, LP as a non‑controlling shareholder. Cencora notes that its fiscal 2026 guidance does not assume the transaction will close within its 2026 fiscal year.
Cencora, Inc. completed a public offering of $3.0 billion of unsecured senior notes across five tranches, with coupons ranging from 3.950% to 5.650% and maturities from 2029 to 2056. The notes are issued under a long-standing indenture with U.S. Bank Trust Company as trustee and include standard covenants on liens, sale-leasebacks, and mergers, plus customary events of default that can accelerate repayment.
Cencora intends to use the net proceeds to repay amounts outstanding under its 364-Day Term Credit Agreement, which helped fund its acquisition of OneOncology, and to use any remaining funds for general corporate purposes. This transaction replaces short-term acquisition financing with longer-term fixed-rate debt.
Cencora, Inc. has priced a multi-tranche senior notes offering totaling $3.0 billion, issuing five series of senior unsecured notes maturing between 2029 and 2056 with coupons ranging from 3.950% to 5.650% in an underwritten registered public offering.
Cencora expects to receive approximately $2.98 billion in net proceeds and plans to use the funds primarily to repay borrowings under its $3.0 billion 364-Day Term Loan Facility used to help finance the OneOncology acquisition, with any remaining proceeds earmarked for general corporate purposes.
Cencora, Inc. filed an 8-K to revise how it presents past financial results, aligning its 2025 Form 10-K disclosures with a new segment structure: U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The change only recasts segment information and does not amend audited financial statements.
Under this structure, fiscal 2025 revenue was $321.3 billion, up 9.3% from 2024, led by U.S. Healthcare Solutions revenue of $285.0 billion, up 9.8%, driven by higher specialty volumes and an additional $7.7 billion of GLP‑1 diabetes and weight‑loss products. Gross profit rose 15.8% to $11.48 billion, and operating income increased 20.8% to $2.63 billion.
Cencora closed the $4.04 billion cash acquisition of Retina Consultants of America in January 2025, plus related contingent consideration, strengthening its retina specialty platform. The company also recorded a $723.9 million goodwill impairment for its PharmaLex reporting unit and reported a 2025 effective tax rate of 30.6%.
Cencora, Inc. reported quarterly results for the fiscal quarter ended December 31, 2025 via a news release furnished as an exhibit, and is holding a conference call and webcast to discuss these results and related matters.
The company also acquired the majority of the outstanding equity interests it did not previously own in OneOncology, a national oncology-focused physician platform, for total cash consideration of approximately $4.6 billion, funded through new debt financing. OneOncology’s affiliated practices and management retained a minority interest, and OneOncology’s future operating results will be included in Cencora’s U.S. Healthcare Solutions segment.
Cencora, Inc. reported that its Board of Directors appointed Ellen G. Cooper as a director, effective January 20, 2026. To accommodate this change, the Board increased its size from ten to eleven members under the company’s Amended and Restated Bylaws.
Ms. Cooper will receive the same compensation and benefits as other non-employee directors under Cencora’s Compensation Policy for Non-Employee Directors, with all cash and equity amounts pro-rated from her appointment date through the company’s 2026 Annual Meeting of Stockholders. The company states there are no arrangements or understandings with other persons regarding her appointment, no family relationships with existing directors or executive officers, and no related-party transactions requiring disclosure. She has not yet been named to any Board committees.
Cencora also issued a news release on January 22, 2026 announcing the appointment, which is furnished as Exhibit 99.1 to this report.
Cencora, Inc. has expanded its financing capacity to support its planned acquisition of OneOncology. The company increased total commitments under its revolving credit facility by $1.0 billion to $5.5 billion, providing additional flexible liquidity.
Cencora also entered into a new senior unsecured term loan agreement totaling $1.5 billion, split into a $500 million tranche maturing two years after draw and a $1.0 billion tranche maturing three years after draw. In addition, the company arranged a separate $3.0 billion 364-day senior unsecured term loan. Proceeds from these loans will help fund the OneOncology purchase price, repay OneOncology’s existing debt, and cover related fees and expenses. Both facilities include leverage covenants generally capped at 4.00 to 1.00, which may temporarily increase to 4.50 to 1.00 when closing a material acquisition, and their funding is conditioned on consummation of the acquisition. These new facilities fully replace previously obtained $4.5 billion bridge financing commitments.
Cencora, Inc. plans to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology from TPG and other shareholders. OneOncology is described as a physician-led national platform supporting independent oncology-focused medical specialty practices. Cencora will pay approximately $3.6 billion for these equity interests and retire $1.3 billion of OneOncology’s existing corporate debt, for total cash consideration of about $5.0 billion.
The company expects to fund the transaction with new debt financing and has obtained $4.5 billion in bridge financing commitments. OneOncology’s affiliated practices and management will retain a minority ownership interest, and completion of the deal is subject to customary closing conditions, including receipt of required regulatory approvals.
Cencora, Inc. (COR) filed an 8‑K announcing its earnings release for the fiscal quarter and year ended September 30, 2025, with the news release furnished as Exhibit 99.1. The company also unveiled a new reporting structure to be used beginning in the first quarter of fiscal 2026: U.S. Healthcare Solutions; International Healthcare Solutions; and Other.
U.S. Healthcare Solutions will include U.S. Human Health (excluding legacy U.S. Consulting Services). International Healthcare Solutions will include Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex. Other will include businesses for which Cencora has begun to explore strategic alternatives, including MWI Animal Health, Profarma, U.S. Consulting Services, and the other components of PharmaLex. Unaudited revised segment information is furnished as Exhibit 99.2. The company scheduled a conference call and webcast at 8:30 a.m. Eastern time.
Cencora, Inc. filed a Form 8-K reporting entry into material agreements. The company executed Amendment No. 2 to the Term Credit Agreement dated September 5, 2025, among the company, the lenders party thereto, and Bank of America, N.A. as administrative agent. On the same date it executed Amendment No. 2 to an Uncommitted Money Market Line Credit Agreement dated September 5, 2025, between the company and Société Générale, New York Branch as lender. The filing references the company's common stock (NYSE: COR), two series of senior notes (2.875% due 2028 and 3.625% due 2032), and certain solicitation and pre-commencement communication rules. The cover page interactive data file is embedded within the Inline XBRL document.
Cencora, Inc. reported that it has reached an agreement, subject to court approval, to resolve a stockholder derivative lawsuit in the Delaware Court of Chancery. The case, brought by Lebanon County Employees’ Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan, alleges breaches of fiduciary duty related to oversight of the company’s controlled substance diversion control programs.
Under a Stipulation and Agreement of Settlement filed on August 15, 2025, insurance carriers would pay the company $111.3 million, less any attorneys’ fees and litigation expenses awarded by the Court to the plaintiffs’ counsel, if the Court approves the settlement. The defendants do not admit liability and expressly deny any wrongdoing. The Court has entered a scheduling order and directed the company to file this report, attach the settlement documents, and post them in its investor relations website.
Cencora, Inc. announced that its Board of Directors has appointed D. Mark Durcan as Chairman of the Board, effective October 1, 2025. Durcan has been a director since September 2015 and has served as Lead Independent Director since March 2023, so this move elevates an experienced, long‑tenured board member to the chair role.
Durcan will succeed Steven H. Collis, who, as previously reported, will retire as Executive Chairman and as a director at the end of Cencora’s fiscal year ending September 30, 2025. When Collis steps down, the size of the Board will decrease from 11 to 10 directors. The company states that Collis’ decision to retire is not due to any disagreement regarding its operations, policies, or practices.